• Explore /
  • Poster
  • / Phase III study evaluating safety and efficacy of the addition of veliparib plus carboplatin versus the addition of carboplatin to standard neoadjuvant chemotherapy in subjects with early-stage triple-negative breast cancer (TNBC).

Phase III study evaluating safety and efficacy of the addition of veliparib plus carboplatin versus the addition of carboplatin to standard neoadjuvant chemotherapy in subjects with early-stage triple-negative breast cancer (TNBC).

Abstract Poster

Authors

Gunter Von Minckwitz

Gunter Von Minckwitz

German Breast Group/University Frankfurt, Neu-Isenburg, Frankfurt, Germany

Gunter Von Minckwitz , Joyce O'Shaughnessy , Eric P. Winer , Norman Wolmark , Charles E. Geyer Jr., Jens Bodo Huober , Sibylle Loibl , William M. Sikov , Michael Untch , Mark D. McKee , Vincent L. Giranda , Hope S. Rugo

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2014 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Breast Cancer - Triple-Negative/Cytotoxics/Local Therapy

Track

Breast Cancer

Sub Track

Triple-Negative Breast Cancer

Clinical Trial Registration Number

NCT02032277

Citation

J Clin Oncol 32:5s, 2014 (suppl; abstr TPS1149)

DOI

10.1200/jco.2014.32.15_suppl.tps1149

Abstract #

TPS1149

Poster Bd #

234B

Abstract Disclosures

Similar Posters

First Author: Charles E. Geyer Jr.

First Author: Peter Schmid

First Author: Tiffany P. Avery

First Author: Jeremy Meyer Force